Table 1.
Clinical features of patient volunteers at time of skin Kaposi sarcoma (KS) biopsy collection.
| Characteristics | Participants (n=13) |
|---|---|
| Age (median in year, IQR) | 39.6 (34.2, 43.4) |
| Gender | all cisgender male |
| Self-reported race/ethnicity, n (%) | |
| White | 3 (23%) |
| Black | 6 (46%) |
| Hispanic | 3 (23%) |
| Not reported | 1 (8%) |
| HIV characteristics | all HIV positive |
| Years from HIV diagnosis to biopsy, median (range) | 10 (0, 35.5) |
| HIV viral load, copies/mL, median (IQR) | 108 (25, 57,591) |
| CD4 T-cell count, cells/pi, median (IQR) | 88 (38, 198.5) |
| Antiretroviral therapy (ART), n (%) | 12 (92%) |
| Duration of ART in months, median (IQR) | 4.1 (0.9, 29.8) |
| Clinical history, n (%) | |
| Initial KS diagnosis, no prior therapy | 7 (54%) |
| Recurrent KS diagnosis, prior systemic KS therapy | 6 (46%) |
| KS and KS associated disease characteristics | |
| Years from KS diagnosis to biopsy, median (range) | 0.4 (0, 9.8) |
| KS diagnosis only, n (%) | 6 (46%) |
| KS and KSHV inflammatory cytokine syndrome, n (%) | 7 (54%) |
| Systemic KS therapy within 4 weeks of biopsy, n (%) | 3 (23%) |
| Stage of KS | T1 stage KS |
| KSHV, copies/106 cells, median (IQR) | |
| Patients with initial KS diagnosis | 600 (1, 48,571) |
| Patients with recurrent KS diagnosis | 1 (0, 1,100) |